Given that summer was underway and the Brexit vote was being digested, July was a surprisingly busy month in pharma and biotech, with a number of noteworthy acquisitions.
Among the most interesting was the small $288,300 deal to help Tiziana Life Sciences (AIM:TILS) to study the secrets of the Sardinian population's health into old age, and the much bigger $1.3 billion acquisition of Gland Pharma by Fosun (HK: 02196), showing evidence of a Chinese company looking to gain a greater presence internationally.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze